Lastly, as much as DMD gene therapy relies on size/complexity of the dystrophin copy delivered to dystrophic cells, efficacy of cell therapy for DMD is linked to the amount of stem/progenitor cells able to reach and engraft the dystrophic muscles and their myogenic potency. Here, DMD is linked to Duchenne muscular dystrophy.